

Cell-Free Biosystems for Biomanufacturing

Chun You and Y.-H. Percival Zhang

Abstract Although cell-free biosystems have been used as a tool for investigating fundamental aspects of biological systems for more than 100 years, they are becoming an emerging biomanufacturing platform in the production of low-value biocommodities (e.g., H₂, ethanol, and isobutanol), fine chemicals, and high-value protein and carbohydrate drugs and their precursors. Here we would like to define the cell-free biosystems containing more than three catalytic components in a single reaction vessel, which although different from one-, two-, or three-enzyme biocatalysis can be regarded as a straightforward extension of multienzymatic biocatalysis. In this chapter, we compare the advantages and disadvantages of cell-free biosystems versus living organisms, briefly review the history of cell-free biosystems, highlight a few examples, analyze any remaining obstacles to the scale-up of cell-free biosystems, and suggest potential solutions. Cell-free biosystems could become a disruptive technology to microbial fermentation, especially in the production of high-impact low-value biocommodities mainly due to the very high product yields and potentially low production costs.

Keywords Biocommodity engineering · Bioeconomy · Biofuels · Biomanufacturing · Cascade enzyme biocatalyst · Cell-free synthetic biology · Synthetic pathway biotransformation

Revised book chapter for *Advances in Biochemical Engineering/Biotechnology*.
Volume: *Future Trends in Biotechnology*.
Volume editor: Jian-Jiang Zhong.

C. You · Y.-H. P. Zhang (✉)
Biological Systems Engineering Department, Virginia Tech, 304 Seitz Hall,
Blacksburg, VA 24061, USA
e-mail: ypzhang@vt.edu

Y.-H. P. Zhang
Institute for Critical Technology and Applied Science (ICTAS), Virginia Tech,
Blacksburg, VA 24061, USA

Y.-H. P. Zhang
Gate Fuels Inc., 2200 Kraft Drive, Suite 1200B, Blacksburg, VA 24060, USA

Contents

1	Introduction.....	108
2	History of Cell-Free Biosystems.....	111
3	Examples of Cell-Free Biosystems for Biomanufacturing.....	112
3.1	Cell-Free Biosystems for Biocommodity Engineering.....	112
3.2	Cell-Free Biosystems for High-Value Product Synthesis.....	117
3.3	Cell-Free Protein Synthesis.....	120
4	Challenges.....	120
4.1	Low-Cost Enzyme Production and Purification.....	121
4.2	Prolonging Enzyme Lifetime.....	123
4.3	Redox Enzyme Engineering.....	127
4.4	Compromised Reaction Conditions.....	128
5	Conclusion.....	128
	References.....	129

1 Introduction

Biomanufacturing is defined as manufacturing the desired products by using living biological organisms (e.g., bacteria, yeasts, plants) or some components from one or several biological organisms. Biomanufacturing has great potential to become a defining technology, especially in the sustainability revolution [1, 2]. Research and development in the fields of biotechnology, bioengineering, and nanomaterials have dramatic impacts on both the products that we are able to create and the ways in which we create them. Potential products that could be produced through biomanufacturing can be listed in an increasing order of selling prices: biocommodities (\$0.3–several US dollars per kg), specialties and biomaterials (tens of dollars per kg), fine chemicals (hundreds of dollars per kg), pharmaceuticals (thousands of dollars/kg), to protein drugs (more than tens of thousands of dollars per kg) (Fig. 1).

Biomanufacturing can be classified into two platforms: living organisms and cell-free biosystems [3, 4]. Living organisms, especially microorganisms, have been utilized for several thousand years to produce a number of products that meet mankind’s needs. As a result, living entities dominate as whole-cell biocatalysts in current biomanufacturing systems. With the development of genetic engineering, protein engineering, systems biology, and synthetic biology, we have gained the ability to modify living organisms to produce natural products at high yields or produce non-natural products. However, the potential of cell-free biosystems in biomanufacturing is often ignored. Herein we define cell-free biosystems composed of more than three catalytic components in one reactor. Thus, we intentionally exclude the use of one to three catalytic components as has been widely used to produce fructose from glucose, produce glucose from starch, and produce chiral alcohols, on large scales [5–9]. Therefore, we do not review traditional enzyme-mediated biocatalysis in this chapter.





Fig. 1 Typical products produced by cell-free biosystems in terms of their selling prices from biocommodities, specialties and renewable materials, and fine chemicals to pharmaceuticals

Table 1 Comparison of cell-free biosystems and a living organism for biomanufacturing

Features	Cell-free biosystems	Living organism
Product yield	Theoretic or high	Low or modest
Product titer	High	Low or modest
Reaction rate	Fast	Slow
Process control	Easy	Difficult
Reaction conditions	Broad	Narrow

Cell-free biosystems have many advantages over living-organism biomanufacturing, such as high product yield, fast reaction rate, high product titer, unprecedented level of control and freedom of design, and broad reaction conditions [3, 4, 10–12] (Table 1). Cell-free biomanufacturing usually gives a yield of the desired product that is often close to a theoretical value when the reactions are irreversible or when the products can be removed in situ. Living systems suffer from low product yields [13, 14] because a significant fraction of carbohydrate and/or energy is used for duplication of cells and formation of side-products when using living organism for manufacturing [15]. For example, all hydrogen-producing microorganisms regardless of whether natural or genetically modified cannot produce hydrogen at yields of more than four moles per mole of glucose, called the Thauer limit [16], because complete oxidation of glucose with water as an oxidant cannot generate any ATP supporting living systems. Conversely, cell-free enzyme cocktails are able to produce nearly 12 moles of hydrogen per mole of glucose [17]. Much higher reaction rates are believed to be possible for cell-free systems than living organisms because (i) neither cell membrane nor wall is present to slow down substrate/product transport, (ii) no energy is needed for transport of substrate/product across the membrane, and (iii) much higher concentrations of biocatalysts can be present in the reactors and no side reactions “slow” the production of the desired product [11]. For example, the highest power density of microbial fuel cells is expected to be around 0.79 mW/cm² [18], while enzymatic fuel cells can generate power densities of up to 8.5–24 mW/cm² [19, 20]. Sometimes too slow productivities mean low potential in industrial biomanufacturing [14, 21]. A high concentration of fermentation products can greatly

Fig. 2 Cell-free biosystems can use a cell extract from one host **a** or purified enzyme from different hosts **b** for biomanufacturing



decrease product separation costs [15] while often inhibiting the growth of living organisms, resulting in low product titers. Cell-free biosystems can be controlled much more easily than living organism because the latter has complicated feedback control for gene regulation, protein transcription, translation, and metabolite fluxes. Therefore, cell-free protein synthesis (CFPS) has become an alternative choice for fast synthesis of recombinant proteins in academic laboratories. Furthermore, cell-free protein synthesis has reached a 100-L milestone [22]. In principal, enzymes, especially thermostable enzymes, can tolerate higher levels of organic solvents or toxic chemical compounds than living organisms, resulting in high product titers. Recently, Sieber and co-workers demonstrated that the enzyme cocktails can produce isobutanol even at a concentration of more than 4 % [23]. Additionally, cell-free biosystems can be conducted under much broader reaction conditions than living organisms, for example in organic solvents, ionic liquids, or in the presence of compounds that are toxic to microorganisms [24]. Most building blocks of cell-free systems are highly exchangeable [25]. For example, high-yield enzymatic hydrogen can be produced by using enzymes isolated or originated from bacterium, yeast, plant, rabbit, and archaeobacterium [26]. Given the advantages of cell-free systems over living organisms, cell-free biosystems are emerging as a powerful biomanufacturing platform to expand the capabilities of natural biological systems without using whole-cell cells.

Cell-free biosystems may be classified into two distinctive platforms according to their preparation method. The first is based on whole cell extract by breaking the cell membrane (Fig. 2a). The second is based on purified enzymes from different sources that are then mixed together (Fig. 2b). The cell extract can be prepared easily but some cellular components may influence the whole system's performance and the whole cell extract has a short half-life time [27, 28]. Systems made of purified components require labor-intensive preparation and seem costly but they can be stabilized after each component is carefully optimized and their

performance is more precisely controlled [14, 29]. Specific attributes of two cell-free biosystems enable their applicability to different products.

2 History of Cell-Free Biosystems

The power of cell-free biosystems has been appreciated as a fundamental research tool for more than 100 years. In 1897, Eduard Buchner discovered a yeast extract (not living yeast) that can convert glucose to ethanol [30], leading to his Nobel Prize in Chemistry in 1907. Later, many scientists used cell-free systems to study the basic biological mechanisms and some have received the Nobel Prize for their efforts. An incomplete winners list includes Arthur Harden and Hans von Euler-Chelpin for their investigation of the fermentation of sugar and fermentative enzymes [31], Otto Warburg for his discovery of the nature and mode of action of respiratory enzymes [32], Carl and Gerty Cori for their discovery of the course of the catalytic conversion of glycogen [33, 34], Hans Krebs for his elucidation of the citric acid cycle [35], Melvin Calvin for his investigation of carbon dioxide assimilation in plants [36], and Nirenberg for his elucidation of the genetic codon by using a cell-free system to translate a poly-uracil RNA sequence [37].

Enzyme-based biotransformation became a manufacturing tool approximately 50 years after the discovery of enzymes. The developments of enzyme-based biotransformation can be divided roughly into three phases:

Phase 1 (1960s)—one-enzyme biotransformation [5, 38]. To solve enzyme stability and recycling issues, enzyme immobilization technology was developed. Invertase may be the first immobilized enzyme used commercially for the production of Golden Syrup by Tate and Lyle during World War II. Tanabe Seiyaku Co. (Japan) started the industrial production of L-methionine by using immobilized aminoacylase in a packed bed reactor in 1969. The Clinton Corn Processing Company (USA) produced fructose syrup using glucose isomerase in 1967. Current annual fructose production exceeds 9 million tons [38] and the longest published working lifetime of immobilized glucose isomerase is 687 days at 55 °C and pH 7.5 (Kato Kagaku, Japan) [5]. Semisynthetic beta-lactamase-resistant beta-lactam antibiotics (e.g., cloxacillin, flucloxacillin) are produced by using amidases [5, 39]. Enzymatic acrylamide production was initiated in 1985 and more than 100,000 metric tons of acrylamide per year is produced by using immobilized nitrile hydratases [38]. Progress is accelerating due to fast developments in protein engineering tools including directed evolution, rational design, and their combination [40], high cell-density fermentation for low-cost recombinant protein production [41], the discovery and utilization of thermoenzymes [42], and enzyme immobilization in nanomaterials [3]. As a result, enzyme-mediated biocatalysis is an alternative choice for numerous transformations from commodities to pharmaceuticals [43, 44].

Phase 2 (1990s)—multienzyme one pot for relatively complicated biotransformation. Multienzyme one pot has numerous benefits compared to single-enzyme

reactors in cascade: fewer unit operations, smaller reactor volume, higher volumetric and space–time yields, shorter cycle times, and less waste generated. Also, by coupling steps together, unfavorable equilibria can be driven towards the formation of desired products [4, 45, 46]. For instance, enzymatic hydrolysis of crystalline cellulose requires a synergetic action of endoglucanase, cellobiohydrolase, and beta-glucosidase because a single enzyme cannot hydrolyze cellulose efficiently [47, 48]. For cofactor-dependent enzyme reactions that consume reduced NAD(P)H, in situ NAD(P)H-regenerated by another enzyme is becoming more and more accepted, especially for the synthesis of high-value chiral compounds in the pharmaceutical industry [3, 49, 50]. Similarly, NAD(P)H is usually generated by using a pair of a hydrogen-donor substrate and a single enzyme, including formate/formate dehydrogenase [51], glucose/glucose dehydrogenase [52], glucose-6-phosphate/glucose-6-phosphate dehydrogenase [42], dihydrogen/hydrogenase [53], and phosphite/phosphite dehydrogenase [54]. In the organic chemistry field, the synthesis of monosaccharides, activated monosaccharides, oligosaccharides, and glycopeptides by using multienzyme one pot has been intensively investigated [55–58].

Phase 3 (2000s)—the utilization of numerous enzymes (i.e., more than three) for implementing very complicated biotransformations. This cell-free biotransformation scheme has three representative directions: (i) cell-free protein synthesis, which utilizes natural protein synthesis systems in cell lysates for fast synthesis of proteins for research purposes and the production of high-value antibodies or other proteins [59, 60], (ii) in vitro synthetic biology for the production of high-value fine chemicals and pharmaceuticals [27, 61–64], and (iii) synthetic pathway biotransformation (SyPaB) for the production of low-value biocommodities [3, 4, 25]. Herein, we focus on the use of more than three catalytic units in one reactor because of its ability to implement biochemical reactions that living organisms cannot.

3 Examples of Cell-Free Biosystems for Biomanufacturing




We highlight several examples of cell-free biosystems so that readers can easily understand the advantages and applications of cell-free biosystems.

3.1 Cell-Free Biosystems for Biocommodity Engineering


Biocommodities are low-value and large-volume products, including biofuels, biochemicals, bioplastics, feed and food [4, 65]. Among them, transportation biofuels have received wide attention due to their nearly zero net greenhouse gas emissions, enhanced energy security, and new biomanufacturing job creation. Because feedstock costs usually account for more than half of biocommodity

selling prices [65, 66], economically viable production of biocommodities requires high product yields and low production costs. Although living microorganisms can duplicate themselves easily and have seemingly low biocatalyst preparation costs, we argue that cell-free biosystems could be an alternative choice due to the unique advantages mentioned earlier: high product yields, fast reaction rates, and potentially very low biocatalyst costs as bulk enzymes become stable and are produced at low cost in the future [3].

There is no question that hydrogen would be the best energy carrier for the transport sector in the future due to the high-energy utilization efficiency through fuel cells and nearly zero pollutants for end-users. Hydrogen can be produced through a number of approaches based on a variety of feedstocks [67]. The production of biohydrogen from low-cost biomass is an excellent solution for producing low-cost hydrogen without net carbon emissions [16, 68, 69]. However, natural and genetically modified hydrogen-producing microbes cannot produce hydrogen in yields of more than four moles hydrogen per mole glucose, called the Thauer limit [14, 16, 70]. Chemical catalysis, such as gasification and aqueous phase reforming, suffers from low product yields due to low chemical selectivity. To solve these problems, a non-natural enzymatic pathway composed of enzymes from bacteria, yeasts, animals, plants, and archae was constructed for generating high-yield hydrogen from starch in 2007 [26] (Fig. 3). The Royal Society (the UK's National Academy of Science) has praised this breakthrough as "the beginning stage of a cheap, green and high-yield hydrogen production" and as a good example of synthetic biology [71]. This synthetic pathway contains (i) a chain-shortening phosphorylation reaction on glucan for producing glucose-1-phosphate (G1P) catalyzed by glucan phosphorylase (Eq. 1); (ii) the conversion of G1P to glucose-6-phosphate (G6P) catalyzed by phosphoglucumutase (Eq. 2); (iii) a pentose phosphate pathway and gluconeogenesis pathway containing ten enzymes for producing 12 NADPH and 6 CO₂ per G6P (Eq. 3); and (iv) the generation of hydrogen from NADPH catalyzed by hydrogenase (Eq. 4).



The combination of Eqs. (1)–(4) results in Eq. 5:



Thermodynamic analysis of Eq. (5) suggests that the overall reactions from starch or cellulosic materials and water are spontaneous and endothermic ($\Delta G = -50$ kJ/mol and $\Delta H^\circ = +598$ kJ/mol) [17, 26]. These reactions are driven




Fig. 3 The synthetic pathway for complete conversion of glucan and water to hydrogen and carbon dioxide. *PPP* pentose phosphate pathway. The enzymes are: *GNP* glucan phosphorylase; *PGM* phosphoglucomutase; *G6PDH* G-6-P dehydrogenase; *6PGDH* 6-phosphogluconate dehydrogenase; *R5PI* phosphoribose isomerase; *Ru5PE* ribulose 5-phosphate epimerase; *TKL* transketolase; *TAL* transaldolase; *TIM* triose phosphate isomerase; *ALD* aldolase; *FBP* fructose-1,6-bisphosphatase; *PGI* phosphoglucose isomerase; and *H2ase*, hydrogenase. The metabolites and chemicals are: *g1p* glucose-1-phosphate; *g6p* glucose-6-phosphate; *6pg* 6-phosphogluconate; *ru5p* ribulose-5-phosphate; *x5p* xylulose-5-phosphate; *r5p* ribose-5-phosphate; *s7p* sedoheptulose-7-phosphate; *g3p* glyceraldehyde-3-phosphate; *e4p* erythrose-4-phosphate; *dhap* dihydroxyacetone phosphate; *fdp* fructose-1,6-diphosphate; *f6p* fructose-6-phosphate; and *Pi* inorganic phosphate. Modified from Ref. [26]

by entropy gains rather than enthalpy losses. The removal of gaseous products, H_2 and CO_2 , from the aqueous phase favors the unidirectional reaction for hydrogen formation. When cellobiose is used as the substrate with a reaction time in the range of one week for a complete reaction, the overall yields of H_2 and CO_2 are 11.2 moles of H_2 and 5.64 moles of CO_2 per mole of anhydroglucose unit of cellobiose, corresponding to 93.1 and 94 % of the theoretical yields (Eq. 5). In principle, the theoretical yield of hydrogen (i.e., $12 H_2$ per glucose equivalent) can be obtained when a continuous reaction is conducted. Over the past few years, intensive efforts have been made pertaining to (i) decreasing enzyme costs and prolonging enzyme lifetime [17, 42, 72–75], (ii) producing all recombinant cytoplasmic enzymes at low costs [42, 76], and (iii) purifying recombinant proteins at

low cost using heat precipitation [42, 75], ammonia sulfate precipitation [77, 78], cellulose-binding module-based adsorption and immobilization [79–82].

Ethanol is the most important gasoline additive because it can decrease air pollutants generated by internal combustion (Otto) engines. It can be produced through microbial anaerobic fermentation by the yeast *Saccharomyces cerevisiae* or by other microorganisms such as *Escherichia coli* and *Zymomonas mobilis* [83]. As early as 1897, Eduard Buchner discovered a yeast extract that converted glucose to ethanol [30]. Much later, Welch and Scopes (1985) started investigating the feasibility of high-yield production of ethanol by a reconstituted yeast glycolytic enzyme system—12 enzymes in total including ten enzymes required for the conversion of glucose to pyruvate and two enzymes required for the conversion of pyruvate to ethanol [84]. In this system, ATP accumulation (i.e., two ATP produced per glucose) prevents complete conversion of glucose to ethanol so that costly ATPase or highly toxic arsenate had to be carefully supplemented in Welch's systems to achieve the high yield of ethanol. To solve this problem, Volker and co-workers designed a non-natural synthetic ethanol-producing pathway comprising six enzyme-catalyzed reactions only [23] (Fig. 4). In it, only four enzymes are required for the conversion of glucose to pyruvate. This synthetic pathway requires neither ATP nor CoA and has a balanced NAD cofactor. Since this pathway has a much lower Gibbs energy than those in yeast and *Z. mobilis*, it is anticipated that this cell-free pathway could have very fast production rates after optimization.

Isobutanol is a four-carbon liquid alcohol that has several advantages over ethanol, such as, lower water absorption, better blending ability, higher energy density, and compatibility with current internal combustion engines [85]. Volker and co-workers also designed a synthetic pathway that can produce isobutanol from glucose by using a cell-free enzyme mixture (Fig. 4). This pathway is composed of two parts: the production of pyruvate from glucose and the generation of isobutanol through the enzymes in valine biosynthesis pathways along with 2-keto-acid decarboxylases (KDC) and alcohol dehydrogenase (ADH). One of the most beautiful aspects of this cell-free system is that this enzyme system can work well even in the presence of 4 % (v/v) isobutanol, whereas low levels of isobutanol (e.g., 1–2 % v/v) stops microbial isobutanol production [86].

Fructose is the sweetest monosaccharide. High-fructose corn syrup (HFCS) is a mixture of fructose and glucose produced from starch, which has simply replaced sucrose as a sweetener. On average, one person in the USA consumes approximately 20 kg of HFCS per year. HFCS is made from starch through a series of enzymatic conversions: (i) starch liquefaction mediated by amylose, (ii) starch saccharification to glucose mediated by glucoamylase, and (iii) conversion of glucose to fructose mediated by glucose (xylose) isomerase (Fig. 5). In this typical process, fructose yield cannot be very high because the last step is reversible and the process runs at equilibrium. To solve this problem, Benner and his coworker designed a novel enzymatic pathway in one pot containing (i) starch phosphorylase, (ii) phosphoglucomutase, (iii) phosphoglucose isomerase, and (iv) fructose-6-phosphatase (Fig. 5). In the last step, the net hydrolysis of fructose-6-phosphate




Fig. 4 Schematic representation of a novel cell-free reaction pathway from glucose to ethanol and isobutanol. In the first part of the reaction (*top box*), glucose is converted into two molecules of pyruvate by four enzymes, then pyruvate can be either directed to ethanol (*lower right box*) or isobutanol synthesis (*lower left box*) in the second part of the reaction cascade. The molecules of CO_2 and H_2O are not shown for clarity. Enzymes are *GDH* glucose dehydrogenase; *DHAD* (gluconate/glycerate) dihydroxy acid dehydratase; *ALDH* glyceraldehyde dehydrogenase; *KDGA* 2-keto-3-desoxygluconate aldolase; *ALS* acetolactate synthase; *KARI* ketolacid reductoisomerase; *KDC* 2-ketoacid decarboxylase; *PDC* pyruvate decarboxylase complex; and *ADH* alcohol dehydrogenase. Modified from Ref. [23]

yields fructose via a transaldolase-catalyzed reaction between fructose-6-phosphate and glyceraldehyde to yield fructose and glyceraldehyde-3-phosphate, which is then hydrolyzed to regenerate glyceraldehyde and inorganic phosphate by using a 3-phosphoglycerate phosphatase. Because the final step is exergonic and irreversible, this process pulls all of the equilibrium intermediates to the desired product. This pathway design illustrates a general idea that the energetics of a pathway should be considered when designing multistep biocatalytic transformations [87].




Fig. 5 Schematic representation of enzymatic fructose production from starch. *GNP* alpha-glucan phosphorylase; *PGM* phosphoglucomutase; *PGI* phosphoglucose isomerase; *F6P* fructose-6-phosphatase. Arrows in red are reversible reactions. Modified from Ref. [87]

3.2 Cell-Free Biosystems for High-Value Product Synthesis

Cell-free systems can be used to produce high-value pharmaceuticals. Organic chemical synthesis plays a dominant role in producing chemicals in the modern pharmaceutical industry, although it is being challenged by enzyme-mediated biocatalysis [44]. For example, fondaparinux (trade name Arixtra) is a synthetic antithrombin III-binding pentasaccharide. Its chemical synthesis involves a large number of chemical synthesis reactions, resulting in very low yields of products (e.g., less than 0.5 %) and the generation of toxic intermediates [88]. As a result, Arixtra is a costly drug. In 2011, Xu et al. reported 10- and 12-step chemoenzymatic synthesis of two structurally homogeneous ultralow molecular weight heparins in 45 and 37 % overall yield, respectively, starting from simple disaccharides [89]. These ultra-low molecular weight heparins display excellent *in vitro* anticoagulant activity and comparable pharmacokinetic properties to Arixtra in a rabbit model. This enzymatic approach may be scaled up easily and shows great potential for a more cost-efficient way to synthesize this important drug class.

Sheldon and his coworker developed a one-pot procedure including four enzymes for the synthesis of carbohydrates from glycerol and an aldehyde (i.e., butanal) (Fig. 6). The first step is the conversion of glycerol to glycerol-3-phosphate at a cost of pyrophosphate mediated by phytase. The second enzyme (glycerol phosphate oxidase) converts glycerol-3-phosphate to DHAP and generates H_2O_2 as a by-product, where a third enzyme catalase is responsible for degrading H_2O_2 to water and oxygen. The fourth enzyme fructose-1,6-bisphosphate aldolase links DHAP and butanal to butanal-DHAP. At the last step, the first enzyme phytase releases phosphate from butanal-DHAP and generates 5-deoxy-5-ethyl-D-xylulose. Although the four enzymes have different optimal pHs, the four enzymes are put in one pot during the whole process. The pH of the reaction vessel





Fig. 6 Schematic representation of enzymatic transformation from glycerol to carbohydrates in one pot with pH shifts. *GPO* glycerol phosphate oxidase; *ALD* fructose-1,6-bisphosphate aldolase. Modified from Ref. [158]

is changed from pH 4.0 to pH 7.0 and then to pH 4.0, ensuring the cascading reactions occur in the desired order. The phytase on/off-switch at its respective pH 4.0 and 7.0 was the key to controlling phosphorylation and dephosphorylation [55].

Cell-free biosystems have been developed for the biosynthesis of radio-labeled purines (ATP and GTP) and pyrimidines (UTP and CTP) from glucose and ammonia, which requires 28 and 18 enzymes, respectively [63, 64]. Compared to the chemical synthesis, both purine and pyrimidine biosynthesis pathways can be reconstructed *de novo* for the incorporation of isotopes into specific sites. This work enables NMR detection for probing structural and dynamic characteristics of nucleic acids.

Enzymatic fuel cells (EFCs) represent a new type of fuel cell devices that can convert chemical energy stored in fuels into electricity mediated by redox enzymes [4, 90]. EFCs are an appealing micro-power source suitable for powering portable electronics because they have a number of features such as high-energy storage density; no flammability or explosion risk; biodegradability; low fuel costs; no costly, rare or heavy metals needed; and rapid “recharge” by injecting a sugar solution [91]. Nearly all EFCs extract only a small fraction of chemical energy in fuels by utilizing only one or a few oxidoreductase enzymes. The complete oxidation of fuels into electricity through engineered cascade pathways would have four benefits: (i) high energy utilization efficiency, (ii) high energy storage density, (iii) low product inhibition, and (iv) high power density [4, 92–94]. EFCs can utilize a large range of chemical compounds as fuels, including methanol, ethanol, glycerol, pyruvate, and glucose (these fuels are listed in increasing order of carbon number in the compound). To increase the fuel utilization efficiency, cascade enzymes can be employed. For example, three cascading redox enzymes have been used in an anode for the complete oxidization of one-carbon methanol to CO₂ [95].

Fig. 7 Schematic representation of complete oxidation of glucose for electricity generation through six enzymes. Modified from Ref. [100]



Similarly, two-carbon ethanol has been oxidized using an 11-enzyme pathway to generate more electrons [96]. Three-carbon glycerol and pyruvate have been oxidized using two cascading dehydrogenases [97] and enzymes in the Krebs cycle [98, 99], respectively. Furthermore, Minter et al. have proposed the complete oxidation of glucose using glycolysis and the TCA cycle [92]. Their pathway design is more complicated than the one proposed here and involves ATP/GTP and acetyl-CoA. However, acetyl-CoA and ATP are labile and cannot be utilized for an extended period of time. Recently, Xu and Minter [100] published another paper on glucose oxidation to CO_2 through a new pathway that does not involve ATP and acetyl-CoA (Fig. 7). However, this design suffers from a very low power density because aldolase that breaks the C–C bond has a very low activity on non-phosphorylated carbohydrates [101, 102].

Zhang and coworkers utilized four thermophilic enzymes in cascade for deep oxidation of glucose without the use of ATP [94]. Polyphosphate glucokinase converts glucose to glucose-6-phosphate using low-cost, stable polyphosphate rather than costly ATP [81]. Two NAD-dependent dehydrogenases (glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase) that were immobilized on the bioanode were responsible for generating two NADH per glucose-6-phosphate (i.e., four electrons were generated per glucose via a

diaphorase-vitamin K(3) electron shuttle system at the anode). When the temperature was increased to 50 °C, the maximum power density increased to 0.322 mW/cm⁻², which was approximately eight times higher than that based on mesophilic enzymes at the same temperature. These results suggest that the deep oxidation of glucose could be achieved by using multiple dehydrogenases in synthetic cascade pathways and that high power output could be achieved by using thermostable enzymes at elevated temperatures.

3.3 Cell-Free Protein Synthesis

While cell-free protein synthesis (CFPS) has been used for decades as a foundational research tool for understanding transcription and translation, recent advances have made possible cost-effective micro-scale to manufacturing scale synthesis of complex proteins [22]. CFPS is becoming a more acceptable tool for the fast synthesis of recombinant proteins, especially when the proteins are *in vivo* cytotoxic, regulatory, or unstable proteins that are difficult to express in living cells and/or the proteins contain unnatural amino acids [10, 59, 103]. CFPS is usually conducted by using a crude cell lysate from any given organism (e.g., bacterial, plant, or animal cells) supplemented with the DNA template encoding the desired protein, NTPs, a highly processive RNA polymerase, amino acids, and an energy supply while the cell lysate provides the translational machinery, accessory enzymes, tRNA, and cofactors [10]. The use of cell lysate greatly simplifies CFPS but it may have some negative impacts due to other cellular components in cell extracts, for example, a rapid depletion of energy charge [59] and the degradation of protein products or template nucleic acids by proteases or nucleases [29]. In 2001, Shimizu et al. reported a protein-synthesizing system reconstituted from recombinant tagged protein factors purified to homogeneity [29]. The system – termed the “protein synthesis using recombinant elements” (PURE) system—contains all necessary translation factors, purified with high specific activity, and allows efficient protein production. This system has more than 100 well-defined molecules for implementing this complicated protein biosynthesis. The PURE system exhibits high translational efficiency with the added advantage of simple manipulation of reaction conditions and easy purification of untagged protein product. As a result, New England Biolabs Inc. sells the PURE fast protein synthesis kit.

Currently CFPS can produce protein in yields exceeding grams of target protein per liter of reaction volume, in batch reactions lasting multiple hours, with cost decreases to several orders of magnitude, and at scales reaching the 100-L milestone by SutroBio [11]. These advances have inspired new applications in the synthesis of protein libraries for functional genomics and structural biology, the production of protein therapeutics [104], personalized medicines [105], vaccines [106], short antimicrobial peptides [107], and the expression of virus-like particles, among others.

4 Challenges

The potential of cell-free biosystems for biomanufacturing is often ignored or underappreciated by many bioengineers and scientists because this paradigm shift is an out-of-the-box solution so that most do not realize that technological breakthroughs in other fields may be game changing in their field. A good example is no-till farming replacing tilling or discing farmland. Mankind has tilled land for thousands of years so it was easy to forget that the primary goal of tilling was to kill weeds. Beveridge described it as conditional thinking in his famous book entitled “The art of Scientific Investigation” [108]. Even long after the invention of selective herbicides and complementary herbicide-resistant seeds, farmers continued to till their land due to the ruling paradigm. The situation changed when several agricultural engineering pioneers in the nonpoint water pollution field realized that tilling was not necessary with proper herbicide and improved seed use. In reality, these no-tilling pioneers did not invent any new technologies but proposed a new concept to solve a key problem in their field. Now no-till farming is widely adopted because of the environmental and economic benefits [109]. Similarly, doubts regarding cell-free biosystems may include (i) enzymes cannot be produced and purified at low cost, (ii) enzymes are not stable enough, (iii) coenzymes are expensive and labile, and (iv) optimal conditions for numerous enzymes are different (Table 2). To address the above challenges, the respective solutions are listed in Table 2.

4.1 Low-Cost Enzyme Production and Purification

Cell-free protein synthesis usually uses cell extracts to decrease enzyme costs, while most cell-free biosystems prefer using partially purified enzymes that avoid unnecessary side-reactions and may prolong reaction time up to weeks, months, or even years. Low-cost production of bulk enzymes has been achieved but most academic researchers do not know this because most purchase costly enzymes from Sigma or other enzyme vendors. For example, bulk enzymes, such as protease and amylase produced by *Bacillus* sp., cellulase produced by *Trichoderma* and *Aspergillus* sp., have selling prices of ca. 5–10 US dollars per kg of dry protein [4, 110]. The cost of protein production is highly related to its expression level. The higher the expression level, the lower the cost of the purified protein. Codon usage optimization is a common way to enhance recombinant protein expression levels. For example, more than 500-fold improvement in the expression of soluble *Thermotoga maritima* 6-phosphogluconate dehydrogenase has been achieved in *E. coli* by codon usage optimization, accounting for >30 % of the total cellular protein [42]. Some recombinant formate dehydrogenase expression levels in *E. coli* are as high as 50 % cellular proteins [111]. It is estimated that current costs of recombinant proteins produced by *E. coli* BL 21 are approximately 100 US

Table 2 Challenges of cell-free systems and respective solutions

Challenge	Solution	Ref
Recombinant protein expression	High-cell density fermentation	Shiloach and Fass [41], Studier [160]
Enzyme purification	Secretory protein	Zhang [4]
	Cell extract	Bujara et al. [27], Swartz [28]
	Heat precipitation	Wang and Zhang [42], Sun et al. [75]
	Ammonia sulfate precipitation	Zhang and Mielenz [77], Scopes [78]
	Simple adsorption and immobilization	Liao et al. [81], Myung et al. [82]
	Resin-free chromatographic separation	Banki et al. [161]
	Fusion proteins	Zhang [114], Iturrate et al. [162], Bulow et al. [163]
	Multienzyme co-purification and immobilization	You et al. [112], Chen et al. [164], Nahalka et al. [165]
Enzyme stability	Thermostable enzymes	Table 3
	Enzyme immobilization	Demain and Vaishnav [166], Kirk et al. [167]
	Enzyme engineering through rational design and/or directed evolution	Ye et al. [40]
Costly and labile coenzymes	Coenzyme immobilization and recycling	Liu and Wang [168]
	Use of stable and low-cost biomimetic coenzyme	Campbell et al. [142], Ryan et al. [151], Campbell et al. [157]
Different optimal conditions for enzymes	Compromised reaction conditions	Zhang et al. [26]
	Adjusted reaction conditions in terms of time	Schoevaart et al. [55], Schoevaart et al. [158]
	Discovery of enzymes from one source	Zhang [4], Wang and Zhang [42], Myung et al. [74], Sun et al. [75]
	Engineered enzymes	Ye et al. [40], Chen and Arnold [169]

dollars per kg of dry protein including materials, labor, and capital depreciation [43]. As enzyme production is scaled up, production costs would decrease further. Dr. Tao at EnzymeWorks (China) pointed out that current enzyme costs in his company were approximately 70 US dollars per kg of enzyme because they can grow the *E. coli* cell densities of more than 100 g dry cell weight per liter without the use of costly pure oxygen (personal communication). It is anticipated that the cost of bulk recombinant enzymes will decrease greatly when their markets are ready.

The impression of costly enzyme purification is often gained from high-purity enzymes produced by academic labs and for pharmaceutical protein drugs, which are purified through a series of chromatographic methods. However, cell-free bio-systems can utilize relatively low-quality enzymes as building blocks. Please bear in mind that cell extracts without purification could work well. In addition, several

low-cost scalable protein purifications are available and have been developed recently. For example, ammonia sulfate precipitation can be used as the first step of most protein purifications [77]. Instead of using commercial costly protein purification resins like Ni-NTA resin, and glutathione Sepharose 4B, low-cost cellulosic materials can be used for protein adsorption/desorption, purification, and immobilization [79–82]. For highly thermophilic enzymes expressed by *E. coli*, heat precipitation could be the simplest way to obtain purified proteins from *E. coli* cell extracts [42, 75]. In our laboratory, we have systematically investigated heat precipitation for the purification of recombinant enzymes produced from *E. coli*. We found that six recombinant enzymes cloned from *T. maritima* and produced in *E. coli*, for example, 6-phosphogluconate dehydrogenase [42], ribose-5-phosphate isomerase [75], aldolase [112], transaldolase [113], transketolase, and xylulokinase can be purified to more than 80–90 % homogeneity by simple heat treatment at 80 °C for 20 min.

Inspired by integrated circuits and natural metabolons [114], we developed a new protein purification method which can enrich, purify, and immobilize three cascade enzymes in one step (Fig. 8a). This method was based on the highly species-specific interaction between cohesins and dockerins from natural cellulosomes [112, 115–117]. A synthetic protein scaffold called scaffoldin was constructed containing a CBM3 module and three cohesins. The CBM3 module can tightly bind on cellulosic materials and cohesins are responsible for binding with the specific dockerin-containing enzymes. Dockerins can be located in either the N- or C-terminal of the target protein [118]. After mixing four cell extracts containing the synthetic scaffoldin and dockerin-containing target proteins with cellulosic materials (e.g., regenerated amorphous cellulose, RAC) and centrifugation, the synthetic three-enzyme metabolon can be purified and immobilized on RAC (Fig. 8a). Triosephosphate isomerase (TIM), aldolase (ALD), and fructose 1,6-bisphosphatase (FBP) were chosen for demonstration purposes. The protein expression levels of dockerin-containing TIM, ALD, and FBP were low (Fig. 8b, Lane 1, 2, 3), but they can be easily enriched and purified by mixing with the synthetic scaffoldin (Lane 5, 6, and 7). The self-assembled three-enzyme metabolon can be obtained in one step (Fig. 8b, Lane 9 and Fig. 8c). Such an enzyme complex also has the unique feature of substrate channeling because of the proximity of the cascade enzymes [114]. This enzyme complex showed more than one order of magnitude enhancements on reaction rates compared to the non-complexed TIM, ALD, and FBP mixture [112] (Fig. 9). In conclusion, numerous methods can decrease enzyme purification costs.

4.2 Prolonging Enzyme Lifetime

Most enzymes in academic laboratories deactivate rapidly, giving researchers an impression that enzymes are not stable. In reality, a few enzymes are very stable with a shelf lifetime of years and have been widely used in daily life, for example,





Fig. 8 **a** Schematic representation for the purification and co-immobilization of the synthetic three-enzyme complex, where the mini-scaffoldin contained three different types of cohesins and one family 3 carbohydrate-binding module, and three enzymes contained respective dockerin. **b** SDS-PAGE analysis of the *E. coli* cell extracts containing the recombinant proteins and RAC pull-down proteins (**a**). Lane M, protein marker; Lane 1–4, cell extract containing TIM-Doc1, ALD-Doc2, FBP-Doc3, and CBM3-Scaf3, respectively; Lane 5, RAC adsorbed mini-scaffoldin, Lane 6–8, RAC adsorbed CBM3-Scaf3 and TIM-Doc1, ALD-Doc2, and FBP-Doc3, respectively; and Lane 9, RAC adsorbed CBM3-Scaf3, TIM-Doc1, ALD-Doc2, and FBP-Doc3. **c** Schematic representation of the self-assembled three-enzyme complex containing TIM-Doc1, ALD-Doc2, FBP-Doc3, and CBM3-Scaf3 containing three different types of cohesins and one family 3 carbohydrate-binding module. Modified from Ref. [159]

Fig. 9 Profiles of fructose-6-phosphate production catalyzed by 2- μ M synthetic enzyme complex (■) and 2- μ M noncomplexed enzyme mixture (●) in 2.5-mM glyceraldehyde-3-phosphate at 60 °C, where the slope of the dashed lines was defined as the initial reaction rate. Modified from Ref. [112]



protease used in detergents, or enzymes used in diabetic test strips. Another famous example is immobilized glucose isomerase lasting for more than 2 years [5].

Enzyme deactivation can be addressed by using thermoenzymes, enzyme immobilization, protein engineering through directed evolution and rational design, and their combination. Our economic analyses pertaining to enzymatic hydrogen production suggest that enzyme costs would be minimal when total turnover numbers (TTN) of all enzymes are larger than 10^7 – 10^8 mol of product per mol of enzyme [4, 77]. When cell-free biosystems are used to produce high value products, acceptable TTN values could be lower. On the basis of our experiences, it is very easy to obtain enzymes with such high TTN values by using natural thermostable enzymes (Table 3). Also, Bommarius and his coworker suggest a very simple way to calculate the TTN value of an enzyme: $TTN = k_{cat}/k_d$, where k_{cat} and k_d are the turn-over number and degradation constant of the enzyme, respectively [119].

The discovery and utilization of thermoenzymes may be the simplest strategy. During the past few years, we have produced a number of thermophilic enzymes in *E. coli*, such as *Clostridium thermocellum* cellodextrin phosphorylase [17], *C. thermocellum* cellobiose phosphorylase [17], *C. thermocellum* glucan phosphorylase [72], *C. thermocellum* phosphoglucomutase [73], *T. maritima* 6-phosphogluconate dehydrogenase [42], *T. maritima* fructose bisphosphatase [74], and *T. maritima* pentose phosphate isomerase [75]. Most of them have TTN values of more than 10^7 as shown in Table 3.

Enzyme immobilization technology has been used to prolong the lifetime of enzymes for a long time [3, 120–122]. For instance, a one-step protein purification and immobilization method has been developed by using low-cost, ultra-high adsorption capacity RAC to adsorb CBM-tagged thermophilic *C. thermocellum* phosphoglucose isomerase (PGI) [82]. The resulting immobilized PGI is highly active and ultra-stable compared to the nonimmobilized PGI, with a TTN of more than 10^9 mol of product per mol of enzyme at 60 °C (Table 3). In the food

Table 3 Examples of stable enzyme building blocks suitable for biocommodity production

EC family	Enzyme name	Microorganism source	Form	Condition	TTN (mol/mol)	Ref.
1.1.1.44	6-Phosphogluconate hydrogenase	<i>T. maritima</i>	Free	80 °C	2.4×10^8	Wang and Zhang [42]
2.2.1.2	Transaldolase	<i>T. maritima</i>	Free	60 °C	1.7×10^7	Huang et al. [113]
3.1.3.11	Fructose 1,6-Bisphosphatase	<i>T. maritima</i>	Free	60 °C	2×10^7	Myung et al. [74]
5.4.2.2	Phosphoglucomutase	<i>C. thermocellum</i>	Free	60 °C	7.1×10^7	Wang and Zhang [73]
5.3.1.5	Xylose (glucose) isomerase		Immobilized	50–60 °C	5.0×10^8	Zhang [4]
5.3.1.6	Ribose-5-phosphate isomerase	<i>T. maritima</i>	Free	60–70 °C	2.2×10^8	Sun et al. [75]
5.3.1.9	Phosphoglucose isomerase	<i>C. thermocellum</i>	Free	60 °C	3.2×10^7	Myung et al. [82]
			Immobilized		1.1×10^9	

industry, immobilized thermophilic glucose isomerase exhibits TTN values of $\sim 5 \times 10^8$ mol of product per mol of enzyme. As a result, no company has a motivation to further prolong the lifetime of this enzyme.

Directed evolution and rational design are powerful approaches to enhancing the thermostability of enzymes [123, 124]. Among different desired properties of engineered enzymes, improving enzyme stability is the easiest. A number of companies and academic laboratories have developed tools for enhancing enzyme lifetime. For example, some enzyme companies and start-ups, such as Codexis, Biomethodes, EnzymeWorks, and Arzeda have demonstrated a number of successful examples for enhancing enzyme stability meeting their customers' needs. For example, Codexis is developing a stable carbonic anhydrase used for capturing high-temperature and low-pH CO_2 from the waste gas of power stations. Also, a combination of rational and random design also have a significant effect on enzyme stability [40].

4.3 Redox Enzyme Engineering

Since both NADP and NAD are not stable in vitro and are costly, it is important to replace them with low-cost biomimetic cofactors especially when cell-free systems are used to produce low-value biofuels and biochemicals (Fig. 10). The bulk prices of NADP, NAD, and nicotinate mononucleotide (NMN) are \$4,500, \$1,500, and \$250 per kg, respectively (personal communication from Alex Tao). Biomimetic cofactors, such as NMN and 1-benzyl-1,4-dihydronicotinamide (BDN), not only have much lower selling prices but also have much better stability.

Redox enzyme engineering was initiated by Perham's group over 20 years ago [125]. By using molecular modeling and comparing amino acid sequences responsible for cofactor binding sites, they changed NADP-preferred glutathione dihydrogen to NAD-preferred by site directed mutagenesis [125]. After this, by using rational design, a number of studies were conducted by swapping cofactor preferences from NADP to NAD [126–132], from NAD to NADP [133–137], and relaxing or broadening cofactor specificity [138–142].

In the 1990s, Lowe and coworkers developed a series of biomimetic analogues of NAD(P) based on triazine dyes [143–147]. Some natural dehydrogenases, such as horse liver alcohol dehydrogenase, can utilize such biomimetic cofactors for implementing redox reactions [146]. Later, Fish et al. determined that the pyrophosphate and adenosine groups associated with NAD are not essential in the hydride transfer and proposed the use of BDN or its analogues to replace natural cofactors [148]. Later, they also showed that wild-type horse liver alcohol dehydrogenase [149] and monooxygenase [150] can work on such biomimics. However, most wild-type redox enzymes cannot work on such biomimics. Clark and Fish demonstrated that a P450 mutant with two amino acid changes can work on these biomimics [151]. Also, another group demonstrated that engineered P450 can utilize Zn dust as an electron source rather than natural cofactors [152, 153]. In




Fig. 10 Structures of natural cofactors and biomimetic cofactors

2011, Zhao and coworkers presented a bio-orthogonal system that catalyzed the oxidative decarboxylation of L-malate with a dedicated biomimetic cofactor, nicotinamide flucytosine dinucleotide, where the redox enzymes were engineered by using saturation mutagenesis of the key amino acid sites [154].

NMN is a precursor of NAD(P) with a much smaller size as compared to NAD(P) (Fig. 6). A few wild-type redox enzymes function using NMN, including liver alcohol dehydrogenase [155] and glutamic dehydrogenase [156]. Recently, Scott et al. demonstrated that engineered *Pyrococcus furiosus* alcohol dehydrogenase has an ability to work on NMN [157].

Although the importance of redox enzyme engineering is gaining recognition for future biomanufacturing [1, 4, 14, 28], redox enzyme engineering remains at an early stage because no framework or general rules exist for engineering redox enzymes on non-natural cofactors [157]. This direction may become one of the top R&D priorities of cell-free biosystems, especially for the production of biocommodities but not for the production of pharmaceuticals that can use more costly natural cofactors.

4.4 Compromised Reaction Conditions

Although numerous enzymes used for the proof-of-concept cell-free biotransformation experiments have different optimal conditions [17, 26], they can work together under compromised conditions (e.g., 30–32 °C) where hyperthermophilic hydrogenase exhibited a very low activity. According to our experiences and literature data, most enzymes from different sources are highly exchangeable in cell-free biosystems [25]. In future applications, we will discover and utilize nearly all enzymes from one source and/or engineer some unmatched enzymes to make their optimal condition match most of other enzymes.

5 Conclusion

The significant advantages provided by cell-free biosystems (Table 1) are motivating their transition from basic research tools to a future biomanufacturing platform. Although a few obstacles to cell-free biosystems remain, all of them can be addressed by using well-known technologies (Table 2). The development of cell-free biosystems may have a similar trend to modern computers. The first prototypes were extremely costly, with low performance, and few applications. After the performance of each part (e.g., CPU, RAM) was improved greatly and standard parts were produced on a large scale, it was simple and less costly to assemble a customized high-performance computer at low prices by using the available standardized parts. Now it is time to discover and develop more stable enzymes as standardized building blocks and engineer redox enzymes that can work with less costly and more stable biomimic cofactors. Cell-free biosystems will eventually become a new biotechnology platform for biomanufacturing numerous products, especially for biocommodities because they are highly cost-sensitive to both product yields (or energy efficiencies) and production costs.

Acknowledgments This work was supported partially by the Shell Game Changer Program, DOE BioEnergy Science Center (BESC), DOE ARPA-E Petro project, the College of Agriculture and Life Sciences Bioprocessing and Biodesign Research Center at Virginia Tech, and NSF SBIR.

References

1. Zhang Y-HP, Huang W-D (2012) Constructing the electricity-carbohydrate-hydrogen cycle for a sustainability revolution. *Trends Biotechnol* 30:301–306
2. Thiel KA (2004) Biomanufacturing, from bust to boom...to bubble? *Nat Biotechnol* 22:1365–1372
3. Zhang Y-HP, Myung S, You C, Zhu ZG, Rollin J (2011) Toward low-cost biomanufacturing through cell-free synthetic biology: bottom-up design. *J Mater Chem* 21:18877–18886
4. Zhang Y-HP (2010) Production of biocommodities and bioelectricity by cell-free synthetic enzymatic pathway biotransformations: challenges and opportunities. *Biotechnol Bioeng* 105:663–677
5. Vasic-Racki D (2006) History of industrial biotransformations—Dreams and realities. In: Liese A, Seebald S, Wandrey C (eds) *Industrial biotransformations*. Wiley-VCH, Weinheim, pp 1–37
6. Lopez-Gallego F, Schmidt-Dannert C (2010) Multi-enzymatic synthesis. *Curr Opin Chem Biol* 14:174–183
7. Ricca E, Brucher B, Schrittwieser JH (2011) Multi-enzymatic cascade reactions: overview and perspectives. *Adv Synth Catal* 353:2239–2262
8. Santacoloma PA, Sin Gr, Gernaey KV, Woodley JM (2010) Multienzyme-catalyzed processes: next-generation biocatalysis. *Org Proc Res Dev* 15:203–212
9. Schoffelen S, van Hest JCM (2012) Multi-enzyme systems: bringing enzymes together in vitro. *Soft Matter* 8:1736–1746
10. Katzen F, Chang G, Kudlicki W (2005) The past, present and future of cell-free protein synthesis. *Trends Biotechnol* 23:150–156

11. Hodgman CE, Jewett MC (2012) Cell-free synthetic biology: thinking outside the cell. *Metab Eng* 14:261–269
12. Bujara M, Schümperli M, Billerbeck S, Heinemann M, Panke S (2010) Exploiting cell-free systems: Implementation and debugging of a system of biotransformations. *Biotechnol Bioeng* 106:376–389
13. Zhang YHP, You C, Chen H, Feng R (2012) Surpassing photosynthesis: High-efficiency and scalable CO₂ utilization through artificial photosynthesis. In *ACS Symposium Series . Recent Advances in Post-Combustion CO₂ Capture Chemistry*. American Chemical Society, pp275–292
14. Zhang Y-HP (2011) Simpler is better: high-yield and potential low-cost biofuels production through cell-free synthetic pathway biotransformation (SyPaB). *ACS Catal* 1:998–1009
15. Huang WD, Zhang Y-HP (2011) Analysis of biofuels production from sugar based on three criteria: Thermodynamics, bioenergetics, and product separation. *Energy Environ Sci* 4:784–792
16. Maeda T, Sanchez-Torres V, Wood TK (2012) Hydrogen production by recombinant *Escherichia coli* strains. *Microb Biotechnol*. doi: [10.1111/j.1751-7915.2011.00282.x](https://doi.org/10.1111/j.1751-7915.2011.00282.x)
17. Ye X, Wang Y, Hopkins RC, Adams MWW, Evans BR, Mielenz JR, Zhang Y-HP (2009) Spontaneous high-yield production of hydrogen from cellulosic materials and water catalyzed by enzyme cocktails. *ChemSusChem* 2:149–152
18. Logan BE (2009) Exoelectrogenic bacteria that power microbial fuel cells. *Nat Rev Microbiol* 7:375–381
19. Gullett W, Schumacher J, Kesmez M, Le D, Minteer SD (2010) High current density air-breathing laccase biocathode. *J Electrochem Soc* 157:B557–B562
20. Zebda A, Gondran C, Le Goff A, Holzinger M, Cinquin P, Cosnier S (2011) Mediatorless high-power glucose biofuel cells based on compressed carbon nanotube-enzyme electrodes. *Nat Commun* 2:370
21. Zhang Y-HP (2010) Renewable carbohydrates are a potential high density hydrogen carrier. *Int J Hydrogen Energy* 35:10334–10342
22. Carlson ED, Gan R, Hodgman CE, Jewett MC (2012) Cell-free protein synthesis: applications come of age. *Biotechnol Adv* 30:1185–1194
23. Guterl J-K, Garbe D, Carsten J, Steffler F, Sommer B, Reiß S, Philipp A, Haack M, Rühmann B, Ketting U, et al (2012) Cell-free metabolic engineering—production of chemicals via minimized reaction cascades. *ChemSusChem*. doi: [10.1002/cssc.201200365](https://doi.org/10.1002/cssc.201200365)
24. Wang Y, Huang W, Sathitsuksanoh N, Zhu Z, Zhang Y-HP (2011) Biohydrogenation from biomass sugar mediated by in vitro synthetic enzymatic pathways. *Chem Biol* 18:372–380
25. Zhang Y-HP, Sun J-B, Zhong J-J (2010) Biofuel production by in vitro synthetic pathway transformation. *Curr Opin Biotechnol* 21:663–669
26. Zhang Y-HP, Evans BR, Mielenz JR, Hopkins RC, Adams MWW (2007) High-yield hydrogen production from starch and water by a synthetic enzymatic pathway. *PLoS One* 2:e456
27. Bujara M, Schümperli M, Pellaux R, Heinemann M, Panke S (2011) Optimization of a blueprint for in vitro glycolysis by metabolic real-time analysis. *Nat Chem Biol* 7:271–277
28. Swartz JR (2011) Transforming biochemical engineering with cell-free biology. *AIChE J* 58:5–13
29. Shimizu Y, Inoue A, Tomari Y, Suzuki T, Yokogawa T, Nishikawa K, Ueda T (2001) Cell-free translation reconstituted with purified components. *Nat Biotechnol* 19:751–755
30. Buchner E (1897) Alkoholische Gärung ohne Hefezellen (Vorläufige Mitteilung). *Berichte der Deutschen Chemischen Gesellschaft* 30:117–124
31. Harden A, Young WJ (1907) The alcoholic ferment of yeast-juice. *Proc Roy Soc London* 77B:405–422
32. Warburg OH (1926) *Über den Stoffwechsel der Tumoren*. Springer, Berlin
33. Cori CF (1931) Mammalian carbohydrate metabolism. *Physiol Rev* 11:143–275
34. Cori GT, Cori CF (1936) The formation of hexosephosphate esters in frog muscle. *J Biol Chem* 116:119–128

35. Krebs HA, Eggleston LV (1944) Metabolism of acetoacetic acid in animal tissues. *Nature* 154:209–210
36. Calvin M, Benson AA (1948) The path of carbon in photosynthesis. *Science* 107:476–480
37. Nirenberg MW, Matthaei JH (1961) The dependence of cell-free protein synthesis in *E. coli* upon naturally occurring or synthetic polyribonucleotides. *Proc Natl Acad Sci USA* 47:1588–1602
38. Michels P, Rosazza J (2009) The evolution of microbial transformations for industrial applications. *SIM News* 2009:36–52
39. Demain AL (2004) Pickles, pectin, and penicillin. *Annu Rev Microbiol* 58:1–42
40. Ye X, Zhang C, Zhang YHP (2012) Engineering a large protein by combined rational and random approaches: stabilizing the *Clostridium thermocellum* cellobiose phosphorylase. *Mol BioSyst* 8:1815–1823
41. Shiloach J, Fass R (2005) Growing *E. coli* to high cell density—a historical perspective on method development. *Biotechnol Adv* 23:345–357
42. Wang Y, Zhang Y-HP (2009) Overexpression and simple purification of the *Thermotoga maritima* 6-phosphogluconate dehydrogenase in *Escherichia coli* and its application for NADPH regeneration. *Microb Cell Fact* 8:30
43. Tufvesson Pr, Lima-Ramos J, Nordblad M, Woodley JM (2011) Guidelines and cost analysis for catalyst production in biocatalytic processes. *Org Proc Res Dev* 15:266–274
44. Bornscheuer UT, Huisman GW, Kazlauskas RJ, Lutz S, Moore JC, Robins K (2012) Engineering the third wave of biocatalysis. *Nature* 485:185–194
45. Daines AM, Maltman BA, Flitsch SL (2004) Synthesis and modifications of carbohydrates, using biotransformations. *Curr Opin Chem Biol* 8:106–113
46. Chi Y, Scroggins ST, Frechet JMJ (2008) One-pot multi-component asymmetric cascade reactions catalyzed by soluble star polymers with highly branched non-interpenetrating catalytic cores. *J Am Chem Soc* 130:6322–6323
47. Lynd LR, Weimer PJ, van Zyl WH, Pretorius IS (2002) Microbial cellulose utilization: fundamentals and biotechnology. *Microbiol Mol Biol Rev* 66:506–577
48. Liao HH, Zhang XZ, Rollin JA, Zhang Y-HP (2011) A minimal set of bacterial cellulases for consolidated bioprocessing of lignocellulose. *Biotechnol J* 6:1409–1418
49. Wildeman SMAD, Sonke T, Schoemaker HE, May O (2007) Biocatalytic reductions: from lab curiosity to “first choice”. *Acc Chem Res* 40:1260–1266
50. Wichmann R, Vasic-Racki D (2005) Cofactor regeneration at the lab scale. *Adv Biochem Eng Biotechnol* 92:225–260
51. Bozic M, Pricelius S, Guebitz GM, Kokol V (2010) Enzymatic reduction of complex redox dyes using NADH-dependent reductase from *Bacillus subtilis* coupled with cofactor regeneration. *Appl Microbiol Biotechnol* 85:563–571
52. Xu Z, Jing K, Liu Y, Cen P (2007) High-level expression of recombinant glucose dehydrogenase and its application in NADPH regeneration. *J Ind Microbiol Biotechnol* 34:83–90
53. Mertens R, Liese A (2004) Biotechnological applications of hydrogenases. *Curr Opin Biotechnol* 15:343–348
54. Johannes TW, Woodyer RD, Zhao H (2007) Efficient regeneration of NADPH using an engineered phosphite dehydrogenase. *Biotechnol Bioeng* 96:18–26
55. Schoevaert R, van Rantwijk F, Sheldon RA (2000) A four-step enzymatic cascade for the one-pot synthesis of non-natural carbohydrates from glycerol. *J Org Chem* 65:6940–6943
56. Zhang J, Shao J, Kowal P, Wang PG (2005) *Enzymatic Synthesis of Oligosaccharides*. Wiley-VCH Verlag GmbH & Co.KGaA, Weinheim
57. Fessner W-D, Helaine V (2001) Biocatalytic synthesis of hydroxylated natural products using aldolases and related enzymes. *Curr Opin Biotechnol* 12:574–586
58. Endo T, Koizumi S (2000) Large-scale production of oligosaccharides using engineered bacteria. *Curr Opin Struct Biol* 10:536–541
59. Wang Y, Zhang Y-HP (2009) Cell-free protein synthesis energized by slowly-metabolized maltodextrin. *BMC Biotechnol* 9:58

60. Calhoun KA, Swartz JR (2005) An economical method for cell-free protein synthesis using glucose and nucleoside monophosphates. *Biotechnol Prog* 21:1146–1153
61. Hold C, Panke S (2009) Towards the engineering of in vitro systems. *J Royal Soc Interface* 6:S507–S521
62. Panke S, Held M, Wubbolts M (2004) Trends and innovations in industrial biocatalysis for the production of fine chemicals. *Curr Opin Biotechnol* 15:272–279
63. Schultheisz HL, Szymczyna BR, Scott LG, Williamson JR (2008) Pathway engineered enzymatic de Novo purine nucleotide synthesis. *ACS Chem Biol* 3:499–511
64. Schultheisz HL, Szymczyna BR, Williamson JR (2009) Enzymatic synthesis and structural characterization of ¹³C, ¹⁵N-poly(ADP-ribose). *J Am Chem Soc* 131:14571–14578
65. Lynd LR, Wyman CE, Gerngross TU (1999) Biocommodity engineering. *Biotechnol Prog* 15:777–793
66. Zhang Y-HP (2011) What is vital (and not vital) to advance economically-competitive biofuels production. *Proc Biochem* 46:2091–2110
67. Zhang Y-HP (2011) Hydrogen production from carbohydrates: a mini-review. *ACS Symp Ser* 1067:203–216
68. Adams MWW, Stiefel EI (1998) Biological hydrogen production: not so elementary. *Science* 282:1842–1843
69. Cortright RD, Davda RR, Dumesic JA (2002) Hydrogen from catalytic reforming of biomass-derived hydrocarbons in liquid water. *Nature* 418:964–967
70. Thauer K, Jungermann K, Decker K (1977) Energy conservation in chemotrophic anaerobic bacteria. *Bacteriol Rev* 41:100–180
71. The Royal Society of the UK (2007) Synthetic biology: call for views. <http://royalsociety.org/page.asp?changes=0&latest=1&id=6731>
72. Ye X, Rollin J, Zhang Y-HP (2010) Thermophilic α -glucan phosphorylase from *Clostridium thermocellum*: cloning, Characterization and enhanced thermostability. *J Mol Cat B Enzym* 65:110–116
73. Wang Y, Zhang Y-HP (2010) A highly active phosphoglucomutase from *Clostridium thermocellum*: Cloning, purification, characterization, and enhanced thermostability. *J Appl Microbiol* 108:39–46
74. Myung S, Wang YR, Zhang Y-HP (2010) Fructose-1,6-bisphosphatase from a hyperthermophilic bacterium *Thermotoga maritima*: Characterization, metabolite stability and its implications. *Proc Biochem* 45:1882–1887
75. Sun FF, Zhang XZ, Myung S, Zhang Y-HP (2012) Thermophilic *Thermotoga maritima* ribose-5-phosphate isomerase RpiB: Optimized heat treatment purification and basic characterization. *Protein Expr Purif* 82:302–307
76. Sun J, Hopkins RC, Jenney FE, McTernan PM, Adams MWW (2010) Heterologous expression and maturation of an NADP-dependent [NiFe]-hydrogenase: a key enzyme in biofuel production. *PLoS One* 5:e10526
77. Zhang Y-HP, Mielenz JR (2011) Renewable hydrogen carrier—carbohydrate: constructing the carbon-neutral carbohydrate economy. *Energies* 4:254–275
78. Scopes RK (1993) Protein purification: principles and practice, 3rd edn. Springer, New York
79. Hong J, Wang Y, Ye X, Zhang Y-HP (2008) Simple protein purification through affinity adsorption on regenerated amorphous cellulose followed by intein self-cleavage. *J Chromatogr A* 1194:150–154
80. Hong J, Ye X, Wang Y, Zhang Y-HP (2008) Bioseparation of recombinant cellulose binding module-protein by affinity adsorption on an ultra-high-capacity cellulosic adsorbent. *Anal Chim Acta* 621:193–199
81. Liao HH, Myung S, Zhang Y-HP (2012) One-step purification and immobilization of thermophilic polyphosphate glucokinase from *Thermobifida fusca* YX: glucose-6-phosphate generation without ATP. *Appl. Microbiol Biotechnol* 93:1109–1117

82. Myung S, Zhang X-Z, Zhang Y-HP (2011) Ultra-stable phosphoglucose isomerase through immobilization of cellulose-binding module-tagged thermophilic enzyme on low-cost high-capacity cellulosic adsorbent. *Biotechnol Prog* 27:969–975
83. Bai FW, Anderson WA, Moo-Young M (2008) Ethanol fermentation technologies from sugar and starch feedstocks. *Biotechnol Adv* 26:89–105
84. Welch P, Scopes RK (1985) Studies on cell-free metabolism: Ethanol production by a yeast glycolytic system reconstituted from purified enzymes. *J Biotechnol* 2:257–273
85. Li S, Wen J, Jia X (2011) Engineering *Bacillus subtilis* for isobutanol production by heterologous *Ehrlich* pathway construction and the biosynthetic 2-ketoisovalerate precursor pathway overexpression. *Appl Microbiol Biotechnol* 91:577–589
86. Atsumi S, Hanai T, Liao JC (2008) Non-fermentative pathways for synthesis of branched-chain higher alcohols as biofuels. *Nature* 451:86–89
87. Moradian A, Benner SA (1992) A biomimetic biotechnological process for converting starch to fructose: thermodynamic and evolutionary considerations in applied enzymology. *J Am Chem Soc* 114:6980–6987
88. Petitou M, van Boeckel CAA (2004) A synthetic antithrombin iii binding pentasaccharide is now a drug! What comes next? *Angew Chem Int Ed* 43:3118–3133
89. Xu Y, Masuko S, Takeddin M, Xu H, Liu R, Jing J, Mousa SA, Linhardt RJ, Liu J (2011) Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. *Science* 334:498–501
90. Moehlenbrock M, Minter S (2008) Extended lifetime biofuel cells. *Chem Soc Rev* 37:1188–1196
91. Zhang Y-HP, Xu J-H, Zhong JJ (2012) A new high-energy density hydrogen carrier - carbohydrate - might be better than methanol. *Int. J. Energy Res.* Epub, doi: [10.1002/er.2897](https://doi.org/10.1002/er.2897)
92. Minter SD, Liaw BY, Cooney MJ (2007) Enzyme-based biofuel cells. *Curr. Opin. Biotechnol.* 18:228–234
93. Cooney MJ, Svoboda V, Lau C, Martin G, Minter SD (2008) Enzyme catalysed biofuel cells. *Energy Environ Sci* 1:320–337
94. Zhu ZG, Sun F, Zhang X, Zhang Y-HP (2012) Deep oxidation of glucose in enzymatic fuel cells through a synthetic enzymatic pathway containing a cascade of two thermostable dehydrogenases. *Biosens Bioelectron* 36:110–115
95. Palmore GTR, Bertschy H, Bergens SH, Whitesides GM (1998) A methanol/dioxygen biofuel cell that uses NAD⁺-dependent dehydrogenases as catalysts: application of an electro-enzymatic method to regenerate nicotinamide adenine dinucleotide at low overpotentials. *J Electroanal Chem* 443:155–161
96. Sokic-Lazic D, Minter SD (2008) Citric acid cycle biomimic on a carbon electrode. *Biosens Bioelectron* 24:939–944
97. Arechederra RL, Treu BL, Minter SD (2007) Development of glycerol/O₂ biofuel cell. *J Power Sources* 173:156–161
98. Sokic-Lazic D, Minter SD (2009) Pyruvate/air enzymatic biofuel cell capable of complete oxidation. *Electrochem Solid-State Lett* 12:F26–F28
99. Moehlenbrock MJ, Toby TK, Waheed A, Minter SD (2010) Metabolon catalyzed pyruvate/air biofuel cell. *J Am Chem Soc* 132:6288–6289
100. Xu S, Minter SD (2011) Enzymatic biofuel cell for oxidation of glucose to CO₂. *ACS Catal* 1:91–94
101. Marsh JJ, Lebherz HG (1992) Fructose-bisphosphate aldolases: an evolutionary history. *Trends Biochem Sci* 17:110–113
102. Hibbert EG, Senussi T, Costelloe SJ, Lei W, Smith MEB, Ward JM, Hailes HC, Dalby PA (2007) Directed evolution of transketolase activity on non-phosphorylated substrates. *J Biotechnol* 131:425–432
103. Boyer ME, Stapleton JA, Kuchenreuther JM, Wang C-w, Swartz JR (2008) Cell-free synthesis and maturation of [FeFe] hydrogenases. *Biotechnol Bioeng* 99:59–67
104. Kim D-M, Swartz JR (2004) Efficient production of a bioactive, multiple disulfide-bonded protein using modified extracts of *Escherichia coli*. *Biotechnol Bioeng* 85:122–129

105. Kanter G, Yang J, Voloshin A, Levy S, Swartz JR, Levy R (2007) Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. *Blood* 109:3393–3399
106. Bundy BC, Franciszkowicz MJ, Swartz JR (2008) *Escherichia coli*-based cell-free synthesis of virus-like particles. *Biotechnol Bioeng* 100:28–37
107. Lee K-H, Kwon Y-C, Yoo SJ, Kim D-M (2010) Ribosomal synthesis and in situ isolation of peptide molecules in a cell-free translation system. *Protein Expr Purif* 71:16–20
108. Beveridge WIB (1960) *The art of scientific investigation*. Vintage, New York
109. Smith P, Powlson DS, Glendining MJ, Smith JU (1998) Preliminary estimates of the potential for carbon mitigation in European soils through no-till farming. *Glob Change Biol* 4:679–685
110. Klein-Marcuschamer D, Oleskowicz-Popiel P, Simmons BA, Blanch HW (2012) The challenge of enzyme cost in the production of lignocellulosic biofuels. *Biotechnol Bioeng* 109:1083–1087
111. Tishkov VI, Popov VO (2006) Protein engineering of formate dehydrogenase. *Biomol Eng* 23:89–110
112. You C, Myung S, Zhang Y-HP (2012) Facilitated substrate channeling in a self-assembled trifunctional enzyme complex. *Angew Chem Int Ed* 51:8787–8790
113. Huang SY, Zhang Y-HP, Zhong JJ (2012) A thermostable recombinant transaldolase with high activity over a broad pH range. *Appl Microbiol Biotechnol* 93:2403–2410
114. Zhang Y-HP (2011) Substrate channeling and enzyme complexes for biotechnological applications. *Biotechnol Adv* 29:715–725
115. Bayer EA, Morag E, Lamed R (1994) The cellulosome—a treasure-trove for biotechnology. *Trends Biotechnol* 12:379–386
116. You C, Zhang X-Z, Sathitsuksanoh N, Lynd LR, Zhang Y-HP (2012) Enhanced microbial cellulose utilization of recalcitrant cellulose by an ex vivo cellulosome-microbe complex. *Appl Environ Microbiol* 78:1437–1444
117. You C, Zhang X-Z, Zhang YHP (2012) Mini-scaffoldin enhanced mini-cellulosome hydrolysis performance on low-accessibility cellulose (Avicel) more than on high-accessibility amorphous cellulose. *Biochem Eng J* 63:57–65
118. Moraïs S, Barak Y, Hadar Y, Wilson DB, Shoham Y, Lamed R, Bayer EA (2011) Assembly of xylanases into designer cellulosomes promotes efficient hydrolysis of the xylan component of a natural recalcitrant cellulosic substrate. *MBio* 2 e00233-11
119. Rogers TA, Bommarius AS (2010) Utilizing simple biochemical measurements to predict lifetime output of biocatalysts in continuous isothermal processes. *Chem Eng Sci* 65: 2118–2124
120. Cao L, Langen Lv, Sheldon RA (2003) Immobilised enzymes: carrier-bound or carrier-free? *Curr Opin Biotechnol* 14:387–394
121. Cao L (2005) Immobilised enzymes: science or art? *Curr Opin Chem Biol* 9:217–226
122. Hartmann M, Jung D (2010) Biocatalysis with enzymes immobilized on mesoporous hosts: the status quo and future trends. *J Mater Chem* 20:844–857
123. Arnold FH, Volkov AA (1999) Directed evolution of biocatalysts. *Curr Opin Chem Biol* 3:54–59
124. Eijssink VG, Bjork A, Gaseidnes S, Sirevag R, Synstad B, van den Burg B, Vriend G (2004) Rational engineering of enzyme stability. *J Biotechnol* 113:105–120
125. Scrutton NS, Berry A, Perham RN (1990) Redesign of the coenzyme specificity of a dehydrogenase by protein engineering. *Nature* 343:38–43
126. Zhang L, Ahvazi B, Szittner R, Vrielink A, Meighen E (1999) Change of nucleotide specificity and enhancement of catalytic efficiency in single point mutants of *Vibrio harveyi* aldehyde dehydrogenase. *Biochemistry* 38:11440–11447
127. Yaoi T, Miyazaki K, Oshima T, Komukai Y, Go M (1996) Conversion of the coenzyme specificity of isocitrate dehydrogenase by module replacement. *J Biochem* 119:1014–1018

128. Bastian S, Liu X, Meyerowitz JT, Snow CD, Chen MMY, Arnold FH (2011) Engineered ketol-acid reductoisomerase and alcohol dehydrogenase enable anaerobic 2-methylpropan-1-ol production at theoretical yield in *Escherichia coli*. *Metab Eng* 13:345–352
129. Rosell A, Valencia E, Ochoa WF, Fita I, Pares X, Farres J (2003) Complete reversal of coenzyme specificity by concerted mutation of three consecutive residues in alcohol dehydrogenase. *J Biol Chem* 278:40573–40580
130. Döhr O, Paine MJI, Friedberg T, Roberts GCK, Wolf CR (2001) Engineering of a functional human NADH-dependent cytochrome P450 system. *Proc Natl Acad Sci USA* 98:81–86
131. Banta S, Swanson BA, Wu S, Jarnagin A, Anderson S (2002) Alteration of the specificity of the cofactor-binding pocket of *Corynebacterium* 2,5-diketo-D-gluconic acid reductase A. *Protein Eng Des Sel* 15:131–140
132. Banta S, Swanson BA, Wu S, Jarnagin A, Anderson S (2002) Optimizing an artificial metabolic pathway: Engineering the cofactor specificity of *Corynebacterium* 2,5-Diketo-D-gluconic acid reductase for use in vitamin C biosynthesis. *Biochemistry* 41:6226–6236
133. Bocanegra JA, Scrutton NS, Perham RN (1993) Creation of an NADP-dependent pyruvate dehydrogenase multienzyme complex by protein engineering. *Biochemistry* 32:2737–2740
134. Mittl PRE, Berry A, Scrutton NS, Perham RN, Schulz GE (1993) Structural differences between wild-type NADP-dependent glutathione reductase from *Escherichia coli* and a redesigned NAD-dependent mutant. *J Mol Biol* 231:191–195
135. Steen IH, Lien T, Madsen MS, Birkeland N-K (2002) Identification of cofactor discrimination sites in NAD-isocitrate dehydrogenase from *Pyrococcus furiosus*. *Arch Microbiol* 178:297–300
136. Watanabe S, Kodaki T, Makino K (2005) Complete reversal of coenzyme specificity of xylitol dehydrogenase and increase of thermostability by the introduction of structural zinc. *J Biol Chem* 280:10340–10349
137. Glykys DJ, Banta S (2009) Metabolic control analysis of an enzymatic biofuel cell. *Biotechnol Bioeng* 102:1624–1635
138. Woodyer RD, van der Donk WA, Zhao H (2003) Relaxing the nicotinamide cofactor specificity of phosphite dehydrogenase by rational design. *Biochemistry* 42:11604–11614
139. Wiegert T, Sahn H, Sprenger GA (1997) The substitution of a single amino acid residue (Ser-116 → Asp) alters NADP-containing glucose-fructose oxidoreductase of *Zymomonas mobilis* into a glucose dehydrogenase with dual coenzyme specificity. *J Biol Chem* 272:13126–13133
140. Katzberg M, Skorupa-Parachin N, Gorwa-Grauslund M-F, Bertau M (2010) Engineering cofactor preference of ketone reducing biocatalysts: A mutagenesis study on a γ -Diketone reductase from the yeast *Saccharomyces cerevisiae* serving as an example. *Int J Mol Sci* 11:1735–1758
141. Sanli G, Banta S, Anderson S, Blaber M (2004) Structural alteration of cofactor specificity in *Corynebacterium* 2,5-diketo-D-gluconic acid reductase. *Protein Eng* 13:504–512
142. Campbell E, Wheeldon IR, Banta S (2010) Broadening the cofactor specificity of a thermostable alcohol dehydrogenase using rational protein design introduces novel kinetic transient behavior. *Biotechnol Bioeng* 107:763–774
143. Burton SJ, Vivian Stead C, Ansell RJ, Lowe CR (1996) An artificial redox coenzyme based on a triazine dye template. *Enzym Microb Technol* 18:570–580
144. Ansell RJ, Dilmaghanian S, Stead CV, Lowe CR (1997) Synthesis and properties of new coenzyme mimics based on the artificial coenzyme Blue N-3. *Enzym Microb Technol* 21:327–334
145. Ansell RJ, Small DAP, Lowe CR (1997) Characterisation of the artificial coenzyme CL4. *J Mol Catal B Enzym* 3:239–252
146. Ansell RJ, Lowe CR (1999) Artificial redox coenzymes: biomimetic analogues of NAD⁺. *Appl Microbiol Biotechnol* 51:703–710
147. Ansell RJ, Small DAP, Lowe CR (1999) Synthesis and properties of new coenzyme mimics based on the artificial coenzyme CL4. *J Mol Recognit* 12:45–56

148. Lo HC, Leiva C, Buriez O, Kerr JB, Olmstead MM, Fish RH (2001) Bioorganometallic chemistry. 13. regioselective reduction of NAD^+ models, 1-benzylnicotinamide triflate and beta-nicotinamide ribose-5'-methyl phosphate, with in situ generated $[\text{Cp}^*\text{Rh}(\text{Bpy})\text{H}]^+$: structure–activity relationships, kinetics, and mechanistic aspects in the formation of the 1,4-NADH derivatives. *Inorg Chem* 40:6705–6716
149. Lo HC, Fish RH (2002) Biomimetic NAD^+ models for tandem cofactor regeneration, horse liver alcohol dehydrogenase recognition of 1,4-NADH derivatives, and chiral synthesis. *Angew Chem Int Ed* 41:478–481
150. Lutz J, Hollmann F, Ho TV, Schnyder A, Fish RH, Schmid A (2004) Bioorganometallic chemistry: biocatalytic oxidation reactions with biomimetic NAD^+/NADH co-factors and $[\text{Cp}^*\text{Rh}(\text{bpy})\text{H}]^+$ for selective organic synthesis. *J Organomet Chem* 689:4783–4790
151. Ryan JD, Fish RH, Clark DS (2008) Engineering cytochrome P450 enzymes for improved activity towards biomimetic 1,4-NADH cofactors. *ChemBioChem* 9:2579–2582
152. Nazor J, Schwaneberg U (2006) Laboratory evolution of P450 BM-3 for mediated electron transfer. *ChemBioChem* 7:638–644
153. Nazor J, Dannenmann S, Adjei RO, Fordjour YB, Ghampson IT, Blanusa M, Roccatano D, Schwaneberg U (2008) Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant. *Protein Eng Des Sel* 21:29–35
154. Ji D, Wang L, Hou S, Liu W, Wang J, Wang Q, Zhao ZK (2011) Creation of bioorthogonal redox systems depending on nicotinamide flucytosine dinucleotide. *J Am Chem Soc* 133:20857–20862
155. Plapp BV, Sogin DC, Dworschack RT, Bohlken DP, Woenckhaus C, Jeck R (1986) Kinetics and native and modified liver alcohol dehydrogenase with coenzyme analogs: isomerization of enzyme-nicotinamide adenine dinucleotide complex. *Biochemistry* 25:5396–5402
156. Fisher HF, McGregor LL (1969) The ability of reduced nicotinamide mononucleotide to function as a hydrogen donor in the glutamic dehydrogenase reaction. *Biochem Biophys Res Commun* 34:627–632
157. Campbell E, Meredith M, Minter SD, Banta S (2012) Enzymatic biofuel cells utilizing a biomimetic cofactor. *Chem Commun* 48:1898–1900
158. Schoevaart R, van Rantwijk F, Sheldon RA (1999) Carbohydrates from glycerol: an enzymatic four-step, one-pot synthesis. *Chem Commun* 31:2465–2466
159. You C, Zhang Y-HP (2012) Self-assembly of synthetic metabolons through synthetic protein scaffolds: one-step purification, co-immobilization, and substrate channeling. *ACS Syn. Biol.* doi: [10.1021/sb300068g](https://doi.org/10.1021/sb300068g)
160. Studier FW (2005) Protein production by auto-induction in high density shaking cultures. *Protein Expr Purif* 41:207–234
161. Banki MR, Feng L, Wood DW (2005) Simple bioseparations using self-cleaving elastin-like polypeptide tags. *Nat Methods* 2:659–662
162. Iturrate L, Sanchez-Moreno I, Doyaguez EG, Garcia-Junceda E (2009) Substrate channelling in an engineered bifunctional aldolase/kinase enzyme confers catalytic advantage for C–C bond formation. *Chem Commun* 2009:1721–1723
163. Bulow L, Ljungcrantz P, Mosbach K (1985) Preparation of a soluble bifunctional enzyme by gene fusion. *Nat Biotechnol* 3:821–823
164. Chen X, Liu Z, Zhang J, Zhang W, Kowal P, Wang P (2002) Reassembled biosynthetic pathway for large-scale carbohydrate synthesis: α -gal epitope producing “superbug”. *ChemBioChem* 4:47–53
165. Nahalka J, Liu Z, Chen X, Wang PG (2003) Superbeads: Immobilization in “sweet” chemistry. *Chem Eur J* 9:372–377
166. Demain AL, Vaishnav P (2009) Production of recombinant proteins by microbes and higher organisms. *Biotechnol Adv* 27:297–306
167. Kirk O, Borchert TV, Fuglsang CC (2002) Industrial enzyme applications. *Curr Opin Biotechnol* 13:345–351

168. Liu W, Wang P (2007) Cofactor regeneration for sustainable enzymatic biosynthesis. *Biotechnol Adv* 25:369–384
169. Chen K, Arnold FH (1993) Turning the activity of an enzyme for unusual environments: sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide. *Proc Natl Acad Sci USA* 90:5618–5622